1. Metformin
2. Sulfonylureas
3. Thiazolidinediones
4. GLP-1 receptor activators

 

2.  Adipocyte products appear to play important roles in the pathogenesis of glycemic abnormality in type 2 diabetes. This is most likely to be benefited by treatment with

1. Metformin
2. Sulfonylureas
3. Thiazolidinediones
4. GLP-1 receptor activators

 

3.  Effects of metformin characteristically are mediated by change in metabolism in the

1. Liver
2. Skeletal muscle
3. Adipocytes
4. Beta cell

 

4.  Incretin analogs are mediated by

1. Liver
2. Skeletal muscle
3. Glucose-dependent insulinotropic polypeptide
4. GLP-1
5. All of the above
6. ‘c’ and ‘d’ only

5.  The use of TZDs is contraindicated in patients with

1. Congestive heart failure
2. Edema or fluid retention
3. Both of the above
4. Neither of the above

6.  True or false: Skilled diabetes practitioners are readily able to bring the majority of diabetic patients to excellent glycemic control levels, with A1c < 6.5%

1. True
2. False
    

7.  Which of the following is NOT a benefit of TZD therapy?

1. glycemic control
2. weight loss
3. reduced liver fat
4. beneficial Beta cell effects

8.  In a new FDA warning, antiepileptic drugs, which may be used in the treatment of painful diabetic neuropathy, have been shown to increase the risk of:
 

1. suicidal behavior
2. lymphoma
3. cardiac arrest
4. stroke